Fig. 1.

Baricitinib plus dexamethasone and remdesivir therapy reverses downward trajectory of hemoglobin and increases platelet count. Daily laboratory results were recorded from routine patient care including hemoglobin (g/dL) [A], white blood cell count (K/cm²) [B], lymphocyte count (K/cm²) [C] and platelet count (K/cm²) [D]. The start date of baricitinib, dexamethasone and remdesivir therapy for each patient was arbitrarily set as day 0. All observations were divided into early (up to day -3) and late periods (up to day + 9). Linear regressions were perform for each variable and a difference in slope tested between before treatment (day -3 to day 0) vs. after treatment (day + 1 to day + 9)